Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE) | SANOFI PASTEUR | UNK | — | OT |
mentioned that they gave a fluzone hd today and after administration, they realized that the patient already had that vaccine a month ago with no reported ae; Initial information received on 05-Nov-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves an unknown age and unknown gender patient reporter mentioned that they gave a INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HD] today and after administration, they realized that the patient already had that vaccine a month ago with no reported ae (adverse event). The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date in 2025, the patient received INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE Suspension for injection in pre-filled syringe (strength, dose, batch and expiry date unknown) via unknown route in unknown administration site for Influenza (Influenza immunisation). On 05-Nov-2025 patient also received another dose of same vaccine with an unknown batch number via unknown route in unknown administration site for Influenza (Influenza immunisation) after administration, they realized that the patient already had that vaccine a month ago with no reported ae (extra dose administered) (latency same day). Information on batch number and expiry date corresponding to the one at time of event occurrence could not be requested Action taken- not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.